Women in Ophthalmology Summer Symposium

Women in Ophthalmology Summer Symposium

Source:

Loh JM, et al. A novel, targeted, blink assisted, thermal eyelid therapy and meibomian gland clearance in the treatment of meibomian gland dysfunction (MGD): A prospective randomized controlled trial (OLYMPIA). Presented at: Women in Ophthalmology Summer Symposium; Aug. 21-23, 2020 (virtual meeting).

Disclosures: Loh reports she is a speaker and consultant for Sight Sciences and is a consultant for Johnson & Johnson Vision.
September 10, 2020
1 min read
Save

OLYMPIA: TearCare treatment improves dry eye signs, symptoms

Source:

Loh JM, et al. A novel, targeted, blink assisted, thermal eyelid therapy and meibomian gland clearance in the treatment of meibomian gland dysfunction (MGD): A prospective randomized controlled trial (OLYMPIA). Presented at: Women in Ophthalmology Summer Symposium; Aug. 21-23, 2020 (virtual meeting).

Disclosures: Loh reports she is a speaker and consultant for Sight Sciences and is a consultant for Johnson & Johnson Vision.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Sight Sciences’ TearCare treatment improved signs and symptoms of dry eye disease statistically significantly and clinically meaningfully, according to a study.

The OLYMPIA study compared a single TearCare treatment to a single LipiFlow (Johnson & Johnson Vision) treatment in a randomized, multicenter, masked study of 235 adults. Seventy percent of participants were women.

Tear breakup time (TBUT) and meibomian gland secretion score were statistically significantly improved at follow-up time points of 2 weeks and 1 month in both groups (P < .0001), thus meeting the study’s primary endpoint of noninferiority. Ocular Surface Disease Index (OSDI) was also statistically significantly improved, Jennifer M. Loh, MD, said in a poster presentation at the virtual Women in Ophthalmology Summer Symposium.

Jennifer M. Loh, MD
Jennifer M. Loh

“Our study showed that a single TearCare treatment statistically and significantly improved the signs and symptoms of dry eye disease in 2 weeks,” Loh said.

Symptomatic relief, demonstrated by at least one OSDI category improvement, was achieved in a greater proportion of patients in the TearCare group than in the LipiFlow group, 72% vs. 59%.

“Even more interesting, a greater proportion of female patients [in the TearCare group] experienced clinically meaningful symptomatic relief in their dry eye symptoms,” Loh said.

Seventy-six percent of female subjects improved by at least one OSDI severity category at 1 month in the TearCare group compared with 56% in the LipiFlow group, according to the poster.